TTY Biopharm Company Limited (TPEX:4105)

Taiwan · Delayed Price · Currency is TWD

83.20

+1.00 (1.22%)

Oct 16, 2026, 1:30 PM CST

Market Cap	20.69B +2.2%
Revenue (ttm)	6.65B +7.0%
Net Income	1.73B +9.5%
EPS	6.96 +9.6%
Shares Out	248.65M
PE Ratio	11.96
Forward PE	11.28
Dividend	4.50 (5.41%)
Ex-Dividend Date	Mar 26, 2026

Volume	1,268,745
Open	82.30
Previous Close	82.20
Day's Range	82.30 - 83.70
52-Week Range	71.60 - 87.00
Beta	0.09
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 5, 2026

About TTY Biopharm Company

TTY Biopharm Company Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical and chemical drugs in Taiwan, the United States, and internationally. The company operates through Oncology Business Unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business Unit, Other Business Unit, and Re-investment Business Unit segments. It offers oncology drugs for the treatment of anticancer and adjunctive therapies under the Lipo-Dox, Lonsurf, UFUR, TS-1, Pexeda, Gemmis, Oxalip, Irino, Epicin,... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1960

Employees 342

Stock Exchange Taipei Exchange

Ticker Symbol 4105

Full Company Profile

Financial Performance

In 2025, TTY Biopharm Company's revenue was 6.45 billion, an increase of 9.49% compared to the previous year's 5.89 billion. Earnings were 1.56 billion, an increase of 7.55%.

Financial Statements